Both BTK and PI3K pathways are activated by the B cell receptor in CLL, and co-inhibition of BTK and PI3K delta (idelalisib) in preclinical model of aggressive lymphomas is reported to significantly improve the efficacy [24]. Here, BTK is linked to lymphoma.